» Articles » PMID: 26541606

Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy

Overview
Journal Science
Specialty Science
Date 2015 Nov 7
PMID 26541606
Citations 1806
Authors
Affiliations
Soon will be listed here.
Abstract

T cell infiltration of solid tumors is associated with favorable patient outcomes, yet the mechanisms underlying variable immune responses between individuals are not well understood. One possible modulator could be the intestinal microbiota. We compared melanoma growth in mice harboring distinct commensal microbiota and observed differences in spontaneous antitumor immunity, which were eliminated upon cohousing or after fecal transfer. Sequencing of the 16S ribosomal RNA identified Bifidobacterium as associated with the antitumor effects. Oral administration of Bifidobacterium alone improved tumor control to the same degree as programmed cell death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination treatment nearly abolished tumor outgrowth. Augmented dendritic cell function leading to enhanced CD8(+) T cell priming and accumulation in the tumor microenvironment mediated the effect. Our data suggest that manipulating the microbiota may modulate cancer immunotherapy.

Citing Articles

Mechanisms of action of intestinal microorganisms and advances in head and neck tumors.

Xialu S, Faqiang M Discov Oncol. 2025; 16(1):303.

PMID: 40072772 PMC: 11903988. DOI: 10.1007/s12672-025-02035-y.


Understanding gut Microbiome changes in Korean children, adolescents, and young adults with hematologic malignancies.

Park M, Jung J, Lee J, Lee E, Lee H, Eom H Ann Hematol. 2025; .

PMID: 40069438 DOI: 10.1007/s00277-025-06293-2.


Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.

Sun J, Song S, Liu J, Chen F, Li X, Wu G NPJ Biofilms Microbiomes. 2025; 11(1):43.

PMID: 40069181 PMC: 11897378. DOI: 10.1038/s41522-025-00678-x.


Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products.

Li D, Lan X, Xu L, Zhou S, Luo H, Zhang X Front Immunol. 2025; 16:1552010.

PMID: 40066456 PMC: 11891355. DOI: 10.3389/fimmu.2025.1552010.


Faecal microbiota transplantation combined with platinum-based doublet chemotherapy and tislelizumab as first-line treatment for driver-gene negative advanced non-small cell lung cancer (NSCLC): study protocol for a prospective, multicentre,....

Wei Y, Qin L, Wu X, Li D, Qian D, Jiang H BMJ Open. 2025; 15(3):e094366.

PMID: 40037667 PMC: 11881178. DOI: 10.1136/bmjopen-2024-094366.


References
1.
Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

2.
Stober C, Brode S, White J, Popoff J, Blackwell J . Slc11a1, formerly Nramp1, is expressed in dendritic cells and influences major histocompatibility complex class II expression and antigen-presenting cell function. Infect Immun. 2007; 75(10):5059-67. PMC: 2044529. DOI: 10.1128/IAI.00153-07. View

3.
Mackey M, Gunn J, Maliszewsky C, Kikutani H, Noelle R, Barth Jr R . Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol. 1998; 161(5):2094-8. View

4.
Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P . Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504(7480):451-5. PMC: 3869884. DOI: 10.1038/nature12726. View

5.
Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W . Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett. 2004; 94(1-2):141-51. DOI: 10.1016/j.imlet.2004.05.003. View